ONS 40th Annual Congress

With the approval and launch of five oral tyrosine kinase inhibitors (TKIs) and one SQ protein synthesis inhibitor—as well as learnings and improvements in monitoring the disease—chronic myeloid leukemia (CML) has steadily transformed to an ever more “chronic” disease. Please join us for an overview of CML that will include the basics of the disease, with a focus on the management of patients in whom at least two TKIs have failed. We will review and discuss a relevant CML patient case and associated course of treatment.

This program is sponsored by Teva Oncology.